Aquestive Therapeutics, Anaphylm, Dibutepinephrine, Epinephrine, Anaphylaxis, FDA, NDA Resubmission, PDUFA, Drug Delivery, Allergy Treatment, Clinical Development

WARREN, N.J., October 15, 2026 Aquestive Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted...